In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aralez Pharmaceuticals Inc.

http://aralez.com/

Latest From Aralez Pharmaceuticals Inc.

Takeda Expects Stronger Net Profit On Lower Tax

Entyvio strong again for Japanese firm as it raises net profit forecast on lower tax costs. Meanwhile, 'Wave 1' pipeline projects are progressing, with simultaneous development in major markets a key goal. 

Commercial Business Strategies

Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m

Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.

Financing Innovation

Another Divestment By Takeda, To China’s Hasten For $322m

Japanese major sheds further non-core assets as it continues to focus on innovation and pay down debt following the Shire acquisition.

China Commercial

Cheplapharm Benefits As Takeda Sheds More Older Products

Japanese major presses on with post-Shire divestments even after passing strategic target.

Business Strategies Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Medical Futures Inc.
    • POZEN Inc.
    • Stellar Pharmaceuticals, Inc. (SLXCF)
    • Tribute Pharmaceuticals Inc.
UsernamePublicRestriction

Register